Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Non-Current Assets (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Non-Current Assets for 4 consecutive years, with $7.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets rose 4.03% to $7.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $28.1 million, a 12.69% increase, with the full-year FY2024 number at $7.0 million, up 14.82% from a year prior.
  • Non-Current Assets was $7.0 million for Q3 2025 at Orchestra BioMed Holdings, up from $6.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $160.2 million in Q2 2022 to a low of $5.9 million in Q2 2024.
  • A 4-year average of $31.4 million and a median of $6.9 million in 2025 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: tumbled 96.07% in 2023, then grew 17.64% in 2025.
  • Orchestra BioMed Holdings' Non-Current Assets stood at $10.9 million in 2022, then crashed by 43.96% to $6.1 million in 2023, then grew by 14.82% to $7.0 million in 2024, then rose by 0.53% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Non-Current Assets are $7.0 million (Q3 2025), $6.9 million (Q2 2025), and $7.1 million (Q1 2025).